The going-concern warning and negative working capital signal acute liquidity risk. Monitor for additional equity or debt financings, which would further dilute common shareholders. The NeuroThera subsidiary's CAD$5.4M raise and loan repayment provide near-term relief but do not resolve the parent-level cash deficit.
Price Chart
Executive Summary
SciSparc filed its H1 2026 interim financials, reporting a net loss of $6.1M (improved from $9.4M in H1 2025) on revenue of $284K (down 38% YoY from $461K). The company disclosed a going-concern qualification, negative working capital of $1.4M, and cash of $4.4M insufficient to fund operations for 12 months. A subsequent event saw NeuroThera raise CAD$5.4M, with SciSparc investing CAD$2.7M, and NeuroThera repaying a $750K loan to SciSparc. The filing is bearish due to the revenue decline, widening operating loss, and explicit going-concern risk.
Key Facts
- Revenue fell 38% YoY to $284K (H1 2026) from $461K (H1 2025)
- Net loss improved to $6.1M from $9.4M, but operating loss widened 80% to $4.9M from $2.7M
- Cash and equivalents $4.4M as of June 30, 2026, down from $4.6M at Dec 31, 2025
- Negative working capital of $1.4M and accumulated deficit of $92.5M
- Going-concern qualification: cash insufficient to fund operations for at least 12 months
- Subsequent event: NeuroThera raised CAD$5.4M; SciSparc invested CAD$2.7M (50% of raise)
- NeuroThera repaid $750K loan to SciSparc on August 13, 2026
- Convertible promissory note of $2.0M principal issued Feb 2026, fair value $2.3M at June 30
- CliniQ acquisition closed June 3, 2026, adding $10.3M excess purchase price and $3.0M goodwill
Financial Impact
Revenue decline of 38% YoY; operating loss increased 80% to $4.9M; cash burn $3.6M from operations in H1 2026
Risk Factors
- Going-concern risk: cash insufficient for 12 months of operations
- Dilution risk: $7.5M remaining under convertible note SPA and SEPA could trigger significant share issuance
- Revenue concentration: all revenue from hemp e-commerce, which declined 38% YoY
- Subsidiary control dilution: SciSparc's stake in NeuroThera fell to 43.86% post-CliniQ, limiting parent benefit from future raises
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-105319 |
| Document: ea0306868-6k_scisparc.htm | 0001213900-26-105319 |
| Document: ea030686801ex99-2.htm | 0001213900-26-105319 |
| Document: 0001213900-26-105319-index-headers.html | 0001213900-26-105319 |
| Document: 0001213900-26-105319-index.html | 0001213900-26-105319 |
| Document: 0001213900-26-105319.txt | 0001213900-26-105319 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 3d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 11d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers